Latest News - AbbVie
Top Corporates Hub
AbbVie
AbbVie Inc. Q2 2026 Earnings Call Summary
31.07.2026 16:50
Moby summary of AbbVie Inc.'s Q2 2026 earnings call
AbbVie Q2 Earnings Call Highlights
31.07.2026 15:04
AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p
AbbVie Beats but Cuts Guidance on $10.9 Billion Acquisition
31.07.2026 15:03
Revenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
31.07.2026 14:00
The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AbbVie Q2 2026 earnings: profit forecast cut for Apogee deal
31.07.2026 13:20
The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share
AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue
31.07.2026 12:59
Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
31.07.2026 12:55
AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.
31.07.2026 12:31
AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.
AbbVie shares fall on earnings miss and weak guidance
31.07.2026 12:27
Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate.
AbbVie (NYSE:ABBV) Shares Slip on Apogee Acquisition Despite In-Line Q2 Results
31.07.2026 12:20
AbbVie Q2 earnings match estimates, but stock dips 4% on Apogee Therapeutics acquisition news amid steady results.
Cannabis Theme's Hidden Strength: Established Players Outshining Pure Plays
30.07.2026 12:05
While pure-play cannabis stocks struggle, defensive opportunities emerge in pharma, staples, and industrial firms like AbbVie, Altria, and Jazz Pharma with strong profitability and value.
JUVÉDERM® Day Returns to U.S. on August 19
30.07.2026 12:00
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 19, 2026, with exclusive JUVÉDERM® offers for Allē Members. Allergan Aesthetics invites aesthetic providers and consumers to join in celebrating JUVÉDERM®'s continued aesthetics leadership as the number one chosen hyaluronic acid (HA) dermal filler collection in the U.S.*,1
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
29.07.2026 07:00
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with severe alopecia areata (AA).1
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
29.07.2026 07:00
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with non-segmental vitiligo (NSV) who are candidates for systemic therapy.1 With this approval, RINVOQ is now the first and only systemic medication approved in the European Union for NSV, the most common form of vitiligo.2
Goldman Sachs uncovers key AbbVie stock signals before earnings
29.07.2026 03:33
AbbVie(ABBV) reports second-quarter results on Friday, July 31, and the mood around the stock has changed. A few months ago, investors were restless. The two drugs carrying the company were doing fine, but everyone already knew that, and the market wanted a new reason to invest. Goldman Sachs went ...
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
28.07.2026 14:00
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
28.07.2026 09:33
Incyte Corporation stock hits a 52-week high on latarcibart and strong Opzelura/Zynyz sales, but valuation & Iclusig demand drive a Hold. Click for an INCY update.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
24.07.2026 14:00
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie: A Dividend Fortress At An Appealing Price Tag
24.07.2026 10:46
AbbVie offers a 2.7% forward dividend yield, outperforming peers by 68%, and maintains a 12-year streak of dividend growth. Find out why ABBV stock is a buy.
Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC’s ‘Final Trades’
24.07.2026 07:53
AbbVie shares gained 1.4% to close at $256.92 on Thursday while Transocean shares rose 0.4% to settle at $5.32 during the session.